Amicus Therapeutics Inc. [FOLD] stock Resumed by BTIG Research analyst, price target now $15

Amicus Therapeutics Inc. [NASDAQ: FOLD] stock went on a downward path that fall over -4.59% on Thursday, amounting to a one-week price decrease of less than -4.27%. The company report on June 22, 2021 that Intuit Launches New Accelerator for AI-focused Startups to Help Communities Overcome Financial Challenges in North America.

The second annual program invites global tech startups with AI-driven solutions to apply to the latest edition of the Intuit Prosperity Accelerator: AI, powered by Highline Beta.

Intuit Inc. (Nasdaq: INTU), a leading global financial platform company known for products such as TurboTax, QuickBooks, Credit Karma and Mint, and Highline Beta, a venture studio and venture capital firm, announced the launch of the Intuit Prosperity Accelerator: AI. The new five-month program aims to leverage the power of artificial intelligence (AI) to advance the financial prosperity of consumers and businesses in North America.

Over the last 12 months, FOLD stock dropped by -40.71%. The average equity rating for FOLD stock is currently 2.60, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $2.28 billion, with 264.37 million shares outstanding and 241.80 million shares in the current float. Compared to the average trading volume of 2.43M shares, FOLD stock reached a trading volume of 2254480 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Amicus Therapeutics Inc. [FOLD]:

BTIG Research have made an estimate for Amicus Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 19, 2021. The new note on the price target was released on May 27, 2021, representing the official price target for Amicus Therapeutics Inc. stock. Previously, the target price had yet another raise to $16, while UBS analysts kept a Buy rating on FOLD stock.

The Average True Range (ATR) for Amicus Therapeutics Inc. is set at 0.39, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 8.56. The Price to Book ratio for the last quarter was 9.20, with the Price to Cash per share for the same quarter was set at 1.60.

FOLD Stock Performance Analysis:

Amicus Therapeutics Inc. [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.27. With this latest performance, FOLD shares dropped by -11.63% in over the last four-week period, additionally sinking by -56.78% over the last 6 months – not to mention a drop of -40.71% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 37.69, with the RSI for the last a single of trading hit 33.98, and the three-weeks RSI is set at 40.08 for Amicus Therapeutics Inc. [FOLD]. The present Moving Average for the last 50 days of trading for this stock 9.61, while it was recorded at 9.23 for the last single week of trading, and 14.83 for the last 200 days.

Insight into Amicus Therapeutics Inc. Fundamentals:

Amicus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 5.00.

FOLD Stock EPS

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amicus Therapeutics Inc. go to -1.00%.

Amicus Therapeutics Inc. [FOLD] Insider Position Details

There are presently around $2,436 million, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 24,387,053, which is approximately 2.271% of the company’s market cap and around 1.10% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 22,861,329 shares of the stock with an approximate value of $199.81 million in FOLD stocks shares; and BLACKROCK INC., currently with $188.1 million in FOLD stock with ownership of nearly -1.625% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

153 institutional holders increased their position in Amicus Therapeutics Inc. [NASDAQ:FOLD] by around 44,919,355 shares. Additionally, 140 investors decreased positions by around 45,805,294 shares, while 24 investors held positions by with 188,035,874 shares. The mentioned changes placed institutional holdings at 278,760,523 shares, according to the latest SEC report filing. FOLD stock had 53 new institutional investments in for a total of 12,845,513 shares, while 64 institutional investors sold positions of 15,079,391 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam